Maria Törnsén Joins Hansa Biopharma as COO and President
Hansa Biopharma AB recently announced the appointment of Maria Törnsén as the Chief Operating Officer (COO) and President for the U.S. operations, effective on the upcoming date in May. This strategic move is expected to bolster the company's executive management team, embracing her extensive expertise in the biopharmaceutical sector.
Extensive Experience in Biopharmaceutical Leadership
Maria Törnsén brings over two decades of experience in global and U.S. operations, holding several key leadership positions in commercially driven roles. Prior to joining Hansa Biopharma, she was the President of North America at Calliditas Therapeutics. There, she managed the U.S. commercial and medical affairs organization until its acquisition by a leading corporation from Japan.
Previous Roles and Achievements
Her impressive career includes senior positions at renowned companies, including Sarepta Therapeutics, Sanofi Genzyme, and Shire plc. At Sarepta, she served as SVP and U.S. General Manager, achieving notable successes in product launches and business expansion. Törnsén has a proven track record of managing a significant global franchise, valued at $1.6 billion, showcasing her capabilities in driving revenue growth and optimizing product launches.
Törnsén's Vision for Hansa Biopharma
Upon her appointment, Törnsén expressed excitement about her new role at Hansa Biopharma, highlighting her eagerness to contribute to the advancement of IDEFIRIX and to meet the anticipated milestones in the latter part of the year. Her background in rare diseases and gene therapy aligns perfectly with the company's strategic direction, as Hansa positions itself for pivotal growth opportunities.
Statements from Leadership
CEO Renée Aguiar-Lucander welcomed Törnsén to the team, emphasizing her significant contributions to building organizations and launching innovative treatments. This expertise will be invaluable as Hansa embarks on its next phase of development.
About Hansa Biopharma
Hansa Biopharma is a dedicated biopharmaceutical company focused on developing groundbreaking therapies for patients dealing with rare immunological disorders. Leveraging a sophisticated IgG-cleaving enzyme technology, the company aims to address critical unmet medical needs in various fields, including autoimmune diseases and transplantation. One of their key therapies, imlifidase, is known to facilitate kidney transplants for highly sensitized patients, and the firm continues to explore innovative solutions within this domain.
Commitment to Innovation
Apart from imlifidase, Hansa is also developing HNSA-5487, a next-generation enzyme with promising redosing potential. The company's strong foundation in research and development signals a commitment to innovation that will drive its mission forward.
Contact Information
For further inquiries, Hansa Biopharma encourages reaching out to their Chief Financial Officer Evan Ballantyne for information. Additionally, Stephanie Kenney serves as the VP of Global Corporate Affairs.
Frequently Asked Questions
Why was Maria Törnsén appointed COO and President?
Maria Törnsén was appointed to leverage her extensive experience in pharmaceutical leadership and drive growth for Hansa Biopharma, particularly in the U.S. market.
What are Hansa Biopharma's main products?
Hansa Biopharma focuses on developing innovative therapies, including imlifidase, an enzyme therapy that enhances kidney transplants for sensitized patients.
How does Hansa Biopharma address rare diseases?
The company utilizes its proprietary technology to tackle unmet medical needs in rare immunological conditions, highlighting its commitment to advancing treatments in this area.
Where is Hansa Biopharma based?
Hansa Biopharma is headquartered in Lund, Sweden, with operations extending throughout Europe and the U.S.
What does the future hold for Hansa Biopharma?
With Törnsén's leadership and the ongoing development of new therapies, Hansa Biopharma is well-prepared for significant growth in the coming years.
